Trending: Merck, Daiichi Sankyo Sign Development, Commercialization Deal
14:07 ET -- Merck is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. After the bell Thursday, Merck and Daiichi Sankyo announced a global development and commercialization collaboration for three Daiichi Sankyo DXd ADCs. On Friday, Merck released data showing its Keytruda in combination with other treatments showed statistically significant improvement in pathological complete response rate for certain breast cancer patients, and that it improved progression-free survival in certain patients with cervical cancer. Dow Jones & Co. owns Factiva. (stephen.nakrosis@wsj.com)
(END) Dow Jones Newswires
October 20, 2023 14:22 ET (18:22 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying